Navigation Links
Celsion Announces ThermoDox's Prominence in Abstracts Presented at the 2nd International MR-Guided Ultrasound Symposium
Date:10/19/2010

COLUMBIA, Md., Oct. 19 /PRNewswire-FirstCall/ -- Celsion Corporation (Nasdaq: CLSN) announced today that two abstracts on the ThermoDox® High Intensity Focused Ultrasound (HIFU) development program have been delivered via oral presentation at the MR-guided Focused Ultrasound 2010 2nd International Symposium.  The abstracts provide strong proof of concept, as well as the rationale and support for future clinical studies, which will combine ThermoDox with MR-guided HIFU for cancer indications.  The symposium is being held October 17-20, 2010 at the Westfields Marriott in Dulles, VA .  

The first abstract, titled "MR-guided High Intensity Focused Ultrasound Enhances Targeted Drug Delivery of Low Temperature Sensitive Liposomes in a Rabbit Vx2 Tumor Model," is authored by Ashish Ranjan from the National Institutes of Health, Bethesda, MD, USA.  The second abstract, titled "Thermally-mediated Localized Drug Release Using MRI-Controlled Focused Ultrasound Hyperthermia," is authored by Robert Staruch from Sunnybrook Health Sciences Centre and University of Toronto, Canada.  Additional co-authors from the two studies are from Duke University, University of Helsinki, Finland, and Philips Healthcare.  The abstracts are available on the company's website site at www.celsion.com.  

"We are delighted to expand our HIFU program to leading oncology research centers in the US, Canada and Europe," said Michael H. Tardugno, Celsion's President and Chief Executive Officer. "We hope to make a seamless transition to clinical studies in these and additional countries based on the preclinical data that has been developed through our joint research agreement with Philips Healthcare.  Celsion and Philips are now well positioned to submit our clinical program for FDA review. Assuming we have agreement, we expect to commence trials in bone cancers next year."

Dr. Nicholas Borys, Chief Medical Officer at Celsion Corporation commented, "The ultrasound and radiology communities have been very supportive of targeted drug delivery applications using MR-guided HIFU.  What started out as a few leading researchers in the US and Europe has now grown to a very large global research community. Similar to our Phase III HEAT study, we expect future HIFU clinical studies will include Asia Pacific, as many researchers from Korea, Taiwan, and China continue to approach us with new oncology applications using MR-guided HIFU."

About ThermoDox®ThermoDox® is a proprietary heat-activated liposomal encapsulation of doxorubicin, an approved and frequently used oncology drug for the treatment of a wide range of cancers including breast cancer. ThermoDox®, which is administered intravenously and in combination with hyperthermia, has the potential to provide local tumor control and improve quality of life. Localized mild hyperthermia (39.5-42 degrees Celsius) releases the entrapped doxorubicin from the liposome. This delivery technology enables high concentrations of doxorubicin to be deposited preferentially in a targeted tumor.

ThermoDox® has also demonstrated evidence of efficacy in a Phase I study for primary liver cancer. Celsion has been granted FDA Orphan Drug designation for ThermoDox® and is conducting a pivotal 600 patient global Phase III study in primary liver cancer under a FDA Special Protocol Assessment.

Additional information on ThermoDox® clinical studies for RCW breast cancer and primary liver cancer can be found at: www.clinicaltrials.gov.

ThermoDox® is a registered trademark of Celsion Corporation.

About CelsionCelsion is dedicated to the development and commercialization of innovative oncology drugs including tumor-targeting treatments using focused heat energy in combination with heat-activated drug delivery systems. Celsion has licensed ThermoDox® to Yakult-Honsha for the Japanese market and has a partnership agreement with Phillips Medical to jointly develop the Company's heat activated liposomal technology in combination with high intensity focused ultrasound to treat difficult cancers. Celsion has research, license, or commercialization agreements with leading institutions such as the National Institutes of Health, Duke University Medical Center, University of Hong Kong, Cleveland Clinic, and the North Shore Long Island Jewish Health System.

For more information on Celsion, visit our website: http://www.celsion.com.

Celsion wishes to inform readers that forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials by others; possible acquisitions of other technologies, assets or businesses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.Investor ContactMarcy NanusThe Trout Group646-378-2927 or mnanus@troutgroup.com
'/>"/>

SOURCE Celsion Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Data Monitoring Committee Unanimously Recommends Continuation of Celsions Phase III ThermoDox® HEAT Study to Treat Primary Liver Cancer
2. Celsion Receives SBIR Grant To Expand Its Technology Platform
3. Celsion Receives Fast Track Designation for ThermoDox® Development Program to Treat Primary Liver Cancer
4. Celsion Announces CFO Departure
5. Aethlon Medical Announces Appointment of Rod Kenley to Its Board of Directors
6. Sysmex America Announces Amerinet Hematology Contract
7. iGPS Announces iGPS bios™, a New Pallet Rental Service Designed Exclusively for the Pharmaceutical and Life Sciences Industries
8. Accium BioSciences Announces $99 Sample Pricing for Its Accelerator Mass Spectrometry (AMS) Measurement Service
9. Althea Technologies Announces the Installation of a High-Speed Prefilled Syringe Line
10. Transcept Pharmaceuticals Announces Preliminary Results From the Intermezzo® Highway Driving Study
11. CoAxia Announces Results of SENTIS Ischemic Stroke Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2017)... CLEVELAND , July 10, 2017  US medical ... billion in 2021, according to Medical Equipment ... released by Freedonia Focus Reports. Continued increases in demand ... the aging of the population and supported by gains ... associated equipment and supplies. New product introductions will also ...
(Date:7/10/2017)... 2017  BDI Group subsidiary Pathway Purchasing Network, ... organization serving specialty pharmacies, home infusion companies and ... significant, value-added member programs designed to help organizations ... and improve access and affordability for patients who ... Pathway has worked ...
(Date:7/10/2017)... RESEARCH TRIANGLE PARK, N.C. , July 10, 2017 ... of a $5m Convertible Note to support the development ... led by Tencent Holdings Limited, a leading Chinese Internet ... Center. This funding will advance multiple infectious disease product ... Founded by Dr. ...
Breaking Medicine Technology:
(Date:7/20/2017)... ... July 20, 2017 , ... TransPixel Volume 2 is a ... in the FCPX timeline. This effect isolates horizontal and vertical lines of pixels and ... either a rotating or flipping animation and can be changed using a drop-down menu. ...
(Date:7/20/2017)... (PRWEB) , ... July 20, 2017 , ... ... law firm headquartered in Houston, is pleased to announce their expansion to the ... affordable housing experience, directors Alysse Hollis and Ronald Bell, and of counsels, John ...
(Date:7/20/2017)... ... 20, 2017 , ... Doctors on Liens, the leading network of medical providers ... directed by Dr. Russell Horine, DC to their exclusive list of medical professionals. Horine ... Horine serving as the clinic director and his son Dr. Lee Horine and daughter-in-law ...
(Date:7/20/2017)... La. (PRWEB) , ... July 20, 2017 , ... The ... the staff. Dr. Dunbar received his BS in Biology from LSU, graduating summa cum ... Medical School Class President. After his residency in St. Louis, Dr. Dunbar moved to ...
(Date:7/20/2017)... ... July 20, 2017 , ... With ... 2014, top travel insurance solution company VisitorsCoverage Inc. has launched TMQuotes, a new ... international travel insurance products online, under their own brand. The online marketplace bridges ...
Breaking Medicine News(10 mins):